WaveMan
WaveMan · Company
TWST · Twist Bioscience Corp
> Search tickers & screens ⌘K
LIVE
← All companies

TWST Twist Bioscience (TWST) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001581280
Quote by TradingView
Form 144 · 40
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
189
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $10.9M priced

What the filings say about TWST

Insiders, 180 days
-$134.3M net sold
10 sellers · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$118.0M
40 notices

Twist Bioscience insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Twist Bioscience Corp insiders sold a net $134.3M of stock across 544 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Laponis Adam
Chief Financial Officer
SELL
2026-10-13 SECtraded 2026-10-09
2,462
$384.8K
-2.0%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Oct 2, 2026.
  • The trade is 2.5% of the 98,114 shares held after it.
  • 5 other insiders sold within 30 days.
  • 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Laponis Adam sold about $384.8K of TWST on Oct 9, 2026; 5 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.
Leproust Emily M.
Chief Executive Officer
SELL
2026-10-07 SECtraded 2026-10-05
1,840
$368.8K
-4.5%
Context
  • 148 earlier Form 4 trades (code P or S) here by this insider (148 sales), the last on Oct 2, 2026.
  • The trade is 0.3% of the 565,468 shares held after it.
  • 5 other insiders sold within 30 days.
  • 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Leproust Emily M. sold about $368.8K of TWST under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.
Leproust Emily M.
Chief Executive Officer
SELL
2026-10-07 SECtraded 2026-10-05
481
$96.8K
-4.5%
Context
  • 148 earlier Form 4 trades (code P or S) here by this insider (148 sales), the last on Oct 2, 2026.
  • The trade is 0.1% of the 564,987 shares held after it.
  • 5 other insiders sold within 30 days.
  • 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Leproust Emily M. sold about $96.8K of TWST under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.
Leproust Emily M.
Chief Executive Officer
SELL
2026-10-07 SECtraded 2026-10-05
1,017
$205.8K
-4.5%
Context
  • 148 earlier Form 4 trades (code P or S) here by this insider (148 sales), the last on Oct 2, 2026.
  • The trade is 0.2% of the 563,970 shares held after it.
  • 5 other insiders sold within 30 days.
  • 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Leproust Emily M. sold about $205.8K of TWST under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.
Leproust Emily M.
Chief Executive Officer
SELL
2026-10-07 SECtraded 2026-10-05
432
$88.0K
-4.5%
Context
  • 148 earlier Form 4 trades (code P or S) here by this insider (148 sales), the last on Oct 2, 2026.
  • The trade is 0.1% of the 563,538 shares held after it.
  • 5 other insiders sold within 30 days.
  • 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Leproust Emily M. sold about $88.0K of TWST under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.
544 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 539 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$134.3M over 180 days
-$119.7M over 90 days
below 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
189 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+20.3% year over year
more than 67% of Pharma & Biotech
Margin
-20.6% net margin
more than 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.1% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Oct 13Chief Financial Officer Laponis Adam sold $1.9M (2 trades, Oct 2 to Oct 9)
Oct 7Chief Executive Officer Leproust Emily M. sold $9.7M under a 10b5-1 plan (10 trades, Oct 1 to Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5President and COO Finn Patrick John sold $4.9M (Oct 2)
Oct 2Officer Leproust Emily M. filed to sell $8.6M by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Officer Finn Patrick John filed to sell $4.9M by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch TWST

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+367.6%12M
-18%+175%+367%+560%2025-102025-122026-022026-042026-062026-082026-10 2026-09-17 · Leproust Emily M. sold $36.7M2026-08-10 · Leproust Emily M. sold $14.2M2026-10-02 · Leproust Emily M. sold $8.6M2026-09-17 · Leproust Emily M. sold $5.1M2026-10-02 · Finn Patrick John sold $4.9M2026-08-18 · Finn Patrick John sold $3.9M2026-09-17 · Leproust Emily M. sold $3.8M2026-08-12 · Leproust Emily M. sold $2.5M2026-09-17 · Leproust Emily M. sold $2.3M2026-09-17 · Leproust Emily M. sold $2.1M2026-02-17 · Green Paula sold $2.1M2026-08-07 · CHESS ROBERT sold $2.0M2026-06-15 · Green Paula sold $2.0M2026-10-02 · Green Paula sold $1.9M2026-08-25 · Leproust Emily M. sold $1.9M2026-08-25 · Leproust Emily M. sold $1.9M2026-08-19 · Cho Dennis sold $1.8M2026-09-17 · Leproust Emily M. sold $1.8M2026-10-02 · Cho Dennis sold $1.8M2026-06-25 · Leproust Emily M. sold $1.8M2026-05-26 · Leproust Emily M. sold $1.6M2026-08-05 · Cho Dennis sold $1.6M2026-05-27 · Leproust Emily M. sold $1.5M2026-08-18 · Finn Patrick John sold $1.5M2026-10-02 · Laponis Adam sold $1.5M2026-09-17 · Leproust Emily M. sold $1.4M2026-02-17 · Finn Patrick John sold $1.4M2026-08-25 · Leproust Emily M. sold $1.4M2026-06-24 · Cho Dennis sold $1.3M2026-08-18 · Finn Patrick John sold $1.2M2026-02-17 · Finn Patrick John sold $1.1M2026-08-18 · Finn Patrick John sold $1.0M2026-09-17 · Leproust Emily M. sold $1.0M2026-05-29 · Cho Dennis sold $990.8K2025-10-30 · Leproust Emily M. sold $986.6K2026-08-25 · Leproust Emily M. sold $979.4K2026-01-13 · Finn Patrick John sold $931.2K2026-08-21 · Leproust Emily M. sold $923.3K2026-02-17 · Finn Patrick John sold $854.4K2026-08-18 · Finn Patrick John sold $761.9K2026-05-12 · JOHANNESSEN JAN sold $673.4K2026-09-17 · Leproust Emily M. sold $643.7K2026-10-23 · Finn Patrick John filed to sell $302.2K2026-10-09 · Laponis Adam filed to sell $384.8K2026-10-05 · Leproust Emily M. filed to sell $919.4K2026-10-02 · Cho Dennis filed to sell $1.8M2026-10-02 · Finn Patrick John filed to sell $4.9M2026-10-02 · Green Paula filed to sell $1.9M2026-10-02 · Laponis Adam filed to sell $1.5M2026-10-02 · Leproust Emily M. filed to sell $8.6M2026-10-02 · WERNER ROBERT F. filed to sell $279.9K2026-10-01 · Leproust Emily M. filed to sell $131.0K2026-09-24 · Leproust Emily M. filed to sell $922.9K2026-09-21 · Cho Dennis filed to sell $57.6K2026-09-21 · Green Paula filed to sell $48.7K2026-09-21 · Leproust Emily M. filed to sell $279.2K2026-09-17 · Leproust Emily M. filed to sell $9.3M2026-09-17 · Leproust Emily M. filed to sell $44.7M2026-09-08 · Cho Dennis filed to sell $50.5K2026-09-08 · Green Paula filed to sell $111.2K2026-09-08 · Leproust Emily M. filed to sell $282.3K2026-09-08 · WERNER ROBERT F. filed to sell $29.2K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TWST: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
5,833,891 sh
$600.2M
Artisan Partners Limited Partnership
4,802,017 sh
$494.0M
FMR LLC
4,703,044 sh
$483.8M
ARK Investment Management LLC
4,549,803 sh
$468.1M
STATE STREET CORP
3,232,532 sh
$332.6M

Congress trades in TWST

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TWST planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Finn Patrick John
Filed 2026-10-23
$302.2K
Laponis Adam
Filed 2026-10-09
$384.8K
Leproust Emily M.
Filed 2026-10-05
$919.4K
Cho Dennis
Filed 2026-10-02
$1.8M
Finn Patrick John
Filed 2026-10-02
$4.9M

TWST mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$120.4M position · as of 2026-07-31
7.7%
Artisan Small Cap Fund
$53.2M position · as of 2026-06-30
5.5%
iShares Genomics Immunology and Healthcare ETF
$9.1M position · as of 2026-07-31
4.8%
Alger Mid Cap 40 ETF
$7.4M position · as of 2026-06-30
4.8%
Global X Genomics & Biotechnology ETF
$2.2M position · as of 2026-05-31
4.0%
American Beacon ARK Transformational Innovation Fund
$6.3M position · as of 2026-06-30
4.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.8M
$928.1K
$4.8M
-63%
+19%
2024
$7.6M
$25.0M
$2.7M
-41%
+16%
2023
$8.0M
$3.2M
$3.1M
-73%
-5%
2022
$5.9M
-$15.0M
$2.5M
-54%
-10%
2021
$1.3M
$18.1M
$728.1K
+41%
+20%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $134.3M sold by insiders over 180 days, 189 funds added last quarter, $118.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLKYMR

TWST financials

Revenue growth
+20.3%
XBRL, annual
Net margin
-20.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$431.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-31.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$93.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2020-12-31 (66 months older than the period end) plus current 2022-09-30 (45 months older than the period end); equity 2026-06-30
Cash flow to debt
-84.92x
TTM operating cash flow over long-term 2020-12-31 (66 months older than the period end) plus current 2022-09-30 (45 months older than the period end)
Return on equity
-29.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-20.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-26.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$9.0B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2020-12-31 (66 months older than the period end) plus current 2022-09-30 (45 months older than the period end), minus cash 2026-06-30
FCF yield
-1.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-092024-092023-092022-09
Revenue$376.6M$313.0M$245.1M$203.6M
Operating income-$136.3M-$220.8M-$217.2M-$234.8M
Net income-$77.7M-$208.7M-$204.6M-$217.9M
EPS (diluted)-1.30-3.60-3.60-4.04
Operating cash flow-$47.6M-$64.1M-$142.5M-$124.4M
Cash$183.0M$226.3M$286.5M$378.7M
SEC XBRL, fiscal years, as known on 2026-10-27

TWST Stock Sonar score 6/7 axes

Find similar shapesCompare

TWST ranks highest on growth (78th percentile) and institutional and government (73rd), and lowest on insider conviction (2nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
67
Inputs
  • Return on equity-29.6% · 67 pct, sector of 545
  • Return on assets-20.8% · 66 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-26.2% · 69 pct, sector of 576
Financial health
46
Inputs
  • Debt to equity0.00x · 84 pct, sector of 352
  • Cash flow to debt-84.92x · 8 pct, sector of 371
Growth
78
Inputs
  • Revenue growth, YoY+20.3% · 67 pct, sector of 505
  • Backlog growth, YoY+63.4% · 90 pct, sector of 40
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$50.0M · 4 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
73
Inputs
  • Funds adding, latest quarter189 · 88 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$315K · 58 pct, sector of 133
Risk and compliance
27
Inputs
  • Short interest, % of float+17.1% · 21 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+13.8% · 34 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TWST filings, in plain words

Are Twist Bioscience insiders buying or selling TWST?

In the 180 days to 2026-10-27, Twist Bioscience insiders were net sellers, a net $134.3M across purchases and sales reported on Form 4, by 10 sellers.

Are there planned insider sales of TWST?

Yes. 40 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $118.0M of stock; the latest, by Finn Patrick John, was filed 2026-10-23.

Read the full summary

In the 180 days to 2026-10-27, Twist Bioscience insiders were net sellers of TWST, a net $134.3M across purchases and sales reported on Form 4 by 10 sellers. 40% of the 115 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 40 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $118.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies